149 | FIRST‐IN‐HUMAN PHASE 1 STUDY OF DR‐01, A NON‐FUCOSYLATED ANTI‐CD94 ANTIBODY IN PATIENTS WITH RELAPSED/REFRACTORY CYTOTOXIC LYMPHOMAS: DOSE ESCALATION AND OPTIMIZATION

Documenti analoghi

• 140 | PHASE 2 TRIAL OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN COMBINATION WITH ACALABRUTINIB IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMAS (LBCL)
  di: P. C. Johnson, et al.
  Pubblicazione: (2025)
• 402 | RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMAS: REPORT ON 641 PATIENTS FROM THE T‐CELL PROJECT 2.0
  di: N. Shokun, et al.
  Pubblicazione: (2025)
• 166 | LACUTAMAB IN PATIENTS WITH RELAPSED AND REFRACTORY SéZARY SYNDROME: LONG TERM FOLLOW‐UP FROM THE TELLOMAK PHASE 2 TRIAL
  di: M. Bagot, et al.
  Pubblicazione: (2025)
• 398 | LACUTAMAB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MYCOSIS FUNGOIDES: LONG TERM FOLLOW‐UP AND TRANSLATIONAL DATA FROM THE TELLOMAK PHASE 2 TRIAL
  di: Y. H. Kim, et al.
  Pubblicazione: (2025)
• 112 | PHASE I STUDY OF SPLIT‐COURSE BRIDGING RADIOTHERAPY (SC‐BRT) PRIOR TO CAR T‐CELL THERAPY FOR RELAPSED/REFRACTORY B‐CELL LYMPHOMAS
  di: B. S. Imber, et al.
  Pubblicazione: (2025)